☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
Otsuka Pharmaceutical
Otsuka Reports Results from the P-III Study of AVP-786 for Treating Agitation in Patients with Dementia Due to Alzheimer's Disease
February 14, 2024
Otsuka Pharmaceutical Reports Results from Two P-III Trials of Centanafadine to Treat ADHD
October 30, 2023
Otsuka Pharmaceutical to Acquire Mindset Pharma for ~$60M
September 1, 2023
Load more...
Back to Home